Difference between revisions of "Brimonidine"
m (robot Adding: es:Brimonidina) |
m (1 revision) |
(No difference)
| |
Latest revision as of 12:13, 20 September 2010
| 260px | |
| Systematic (IUPAC) name | |
|---|---|
|
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Ocular, 1 gtt |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | liver primarily |
| Biological half-life | 3 hours |
| Identifiers | |
| CAS Number | 59803-98-4 |
| ATC code | S01EA05 (WHO) |
| PubChem | CID 2435 |
| IUPHAR/BPS | 520 |
| DrugBank | APRD00034 |
| Chemical data | |
| Formula | C11H10BrN5 |
| Molar mass | 292.135 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Brimonidine (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a drug used to treat open-angle glaucoma or ocular hypertension. Alphagan is also used to induce miosis for people suffering from poor night vision after Lasik or PRK surgery.
It acts via decreasing synthesis of aqueous humor, and increasing the amount that drains from the eye. As a treatment for glaucoma, it is usually given in eyedrop form.
Brimonidine is an α2-adrenergic receptor agonist.
Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the activity of adenylate cyclase. This reduces cAMP and hence aqueous humour production by the ciliary body.
Clinical uses
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
External links
References
- Mosby's Drug Guide for Nurses (7th edition; Skidmore) 2007.
